[
  {
    "ts": null,
    "headline": "Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing",
    "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) stock fell 3.5% and Eli Lilly (NYSE:LLY) shares dropped 3% in after-hours trading Thursday following comments from President Trump regarding potential price reductions for popular weight loss medications.",
    "url": "https://finnhub.io/api/news?id=0844b575bcd9f9aecf53bc7945238ec1f665ecf0acb7af4e069bec07821d3031",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760649751,
      "headline": "Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing",
      "id": 137121701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) stock fell 3.5% and Eli Lilly (NYSE:LLY) shares dropped 3% in after-hours trading Thursday following comments from President Trump regarding potential price reductions for popular weight loss medications.",
      "url": "https://finnhub.io/api/news?id=0844b575bcd9f9aecf53bc7945238ec1f665ecf0acb7af4e069bec07821d3031"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson’s (JNJ) Stock Is Now Positioned To “Challenge Eli Lilly,” Says Jim Cramer",
    "summary": "We recently published Jim Cramer Talked About These 8 Stocks & The Quantum Computing Dip. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) announced yesterday that it would spin off its orthopedics business to allow it to become the largest firm of its kind in the […]",
    "url": "https://finnhub.io/api/news?id=01ca43712277f5673183febd5d5540dda998468a717c506ecc8f8a8d574c70c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760643448,
      "headline": "Johnson & Johnson’s (JNJ) Stock Is Now Positioned To “Challenge Eli Lilly,” Says Jim Cramer",
      "id": 137121702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published Jim Cramer Talked About These 8 Stocks & The Quantum Computing Dip. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) announced yesterday that it would spin off its orthopedics business to allow it to become the largest firm of its kind in the […]",
      "url": "https://finnhub.io/api/news?id=01ca43712277f5673183febd5d5540dda998468a717c506ecc8f8a8d574c70c8"
    }
  },
  {
    "ts": null,
    "headline": "A Look at Eli Lilly’s Valuation Following Landmark Orforglipron Phase 3 Results",
    "summary": "Eli Lilly (LLY) just reported that its investigational pill, orforglipron, achieved every main and secondary goal in two late-stage clinical trials for type 2 diabetes. The data showed better blood sugar control, meaningful weight loss, and cardiovascular improvements compared to both a rival medicine and placebo. See our latest analysis for Eli Lilly. These latest breakthrough trial results have kept the momentum building for Eli Lilly after a year packed with milestones. From the launch of...",
    "url": "https://finnhub.io/api/news?id=fa332f05e4ef75ebc8808477786f9b7bbff2bfa22a6acee7b3119e48cfababac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760642106,
      "headline": "A Look at Eli Lilly’s Valuation Following Landmark Orforglipron Phase 3 Results",
      "id": 137121703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) just reported that its investigational pill, orforglipron, achieved every main and secondary goal in two late-stage clinical trials for type 2 diabetes. The data showed better blood sugar control, meaningful weight loss, and cardiovascular improvements compared to both a rival medicine and placebo. See our latest analysis for Eli Lilly. These latest breakthrough trial results have kept the momentum building for Eli Lilly after a year packed with milestones. From the launch of...",
      "url": "https://finnhub.io/api/news?id=fa332f05e4ef75ebc8808477786f9b7bbff2bfa22a6acee7b3119e48cfababac"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Reiterates Eli Lilly and (LLY) Buy Recommendation",
    "summary": "Guggenheim Reiterates Eli Lilly and (LLY) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=b7af5c091d81d762ce4cf9d86a5a2a7129348a89b720f2012eae064a77ea3376",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760640485,
      "headline": "Guggenheim Reiterates Eli Lilly and (LLY) Buy Recommendation",
      "id": 137107544,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b7af5c091d81d762ce4cf9d86a5a2a7129348a89b720f2012eae064a77ea3376"
    }
  },
  {
    "ts": null,
    "headline": "LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins",
    "summary": "Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.",
    "url": "https://finnhub.io/api/news?id=b6656dc8dd77dacafed03a1e4ec30c4a8d7e7609817ca8888a62441ff8da9e97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760637300,
      "headline": "LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins",
      "id": 137121704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.",
      "url": "https://finnhub.io/api/news?id=b6656dc8dd77dacafed03a1e4ec30c4a8d7e7609817ca8888a62441ff8da9e97"
    }
  },
  {
    "ts": null,
    "headline": "NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio",
    "summary": "Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.",
    "url": "https://finnhub.io/api/news?id=91ab3a087f3862e0b958cd1dcc015cb5fc19945fa11e0ec334f7701f107bc925",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760627400,
      "headline": "NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio",
      "id": 137121705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.",
      "url": "https://finnhub.io/api/news?id=91ab3a087f3862e0b958cd1dcc015cb5fc19945fa11e0ec334f7701f107bc925"
    }
  },
  {
    "ts": null,
    "headline": "Lilly confirms date and conference call for third-quarter 2025 financial results announcement",
    "summary": "Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
    "url": "https://finnhub.io/api/news?id=b15178e62c99faa78a83c5360f59ac131b5df29e797d782a2ed5a955efb85850",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760623200,
      "headline": "Lilly confirms date and conference call for third-quarter 2025 financial results announcement",
      "id": 137106179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
      "url": "https://finnhub.io/api/news?id=b15178e62c99faa78a83c5360f59ac131b5df29e797d782a2ed5a955efb85850"
    }
  },
  {
    "ts": null,
    "headline": "2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades",
    "summary": "These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.",
    "url": "https://finnhub.io/api/news?id=330b9c95826c00fab473562b7572e31e004bf847ccab32732ce13052a0f32db9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760622480,
      "headline": "2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades",
      "id": 137105651,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.",
      "url": "https://finnhub.io/api/news?id=330b9c95826c00fab473562b7572e31e004bf847ccab32732ce13052a0f32db9"
    }
  },
  {
    "ts": null,
    "headline": "How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?",
    "summary": "Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.",
    "url": "https://finnhub.io/api/news?id=488c53523ecc83f8a8b120881f4df87297f15bfa97cd24ccf85343669fdd3a91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760621460,
      "headline": "How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?",
      "id": 137106181,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.",
      "url": "https://finnhub.io/api/news?id=488c53523ecc83f8a8b120881f4df87297f15bfa97cd24ccf85343669fdd3a91"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From Eli Lilly’s Next Earnings Report",
    "summary": "What should investors expect from pharma giant Eli Lilly’s upcoming Q3 results?",
    "url": "https://finnhub.io/api/news?id=9f5cffdfc9885de0338c7b69c57b271b62df7efc23d61473338d3bedbd866332",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760615515,
      "headline": "Here's What to Expect From Eli Lilly’s Next Earnings Report",
      "id": 137106182,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "What should investors expect from pharma giant Eli Lilly’s upcoming Q3 results?",
      "url": "https://finnhub.io/api/news?id=9f5cffdfc9885de0338c7b69c57b271b62df7efc23d61473338d3bedbd866332"
    }
  },
  {
    "ts": null,
    "headline": "Did Viking Therapeutics Just Say \"Checkmate\" to Eli Lilly?",
    "summary": "The smaller drugmaker is looking to disrupt a fast-growing market.",
    "url": "https://finnhub.io/api/news?id=e5ad008d538d3fbd3873a9594dc273fa2129c5a4f101ba8ac38db967f442f1d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760615100,
      "headline": "Did Viking Therapeutics Just Say \"Checkmate\" to Eli Lilly?",
      "id": 137104413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The smaller drugmaker is looking to disrupt a fast-growing market.",
      "url": "https://finnhub.io/api/news?id=e5ad008d538d3fbd3873a9594dc273fa2129c5a4f101ba8ac38db967f442f1d0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s oral GLP-1RA gains fourth Phase III type 2 diabetes win",
    "summary": "The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key secondary endpoints.",
    "url": "https://finnhub.io/api/news?id=e8641e8e7b5efa75947295090f68f153b8a60034ca4862b2fa793329349629c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760612491,
      "headline": "Eli Lilly’s oral GLP-1RA gains fourth Phase III type 2 diabetes win",
      "id": 137104414,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key secondary endpoints.",
      "url": "https://finnhub.io/api/news?id=e8641e8e7b5efa75947295090f68f153b8a60034ca4862b2fa793329349629c4"
    }
  },
  {
    "ts": null,
    "headline": "From Magnificent To Stretched: Rethink U.S. Equity Allocations",
    "summary": "A small number of companies dominate US equity market size and earnings, making investors reliant on the fortunes of a select few.",
    "url": "https://finnhub.io/api/news?id=bcb384d44917522deadb7813a6f0f1fd74ab1db745201614fd17e6bcd5b5a001",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760594640,
      "headline": "From Magnificent To Stretched: Rethink U.S. Equity Allocations",
      "id": 137103600,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2007398242/image_2007398242.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "A small number of companies dominate US equity market size and earnings, making investors reliant on the fortunes of a select few.",
      "url": "https://finnhub.io/api/news?id=bcb384d44917522deadb7813a6f0f1fd74ab1db745201614fd17e6bcd5b5a001"
    }
  },
  {
    "ts": null,
    "headline": "Erste Group Upgrades Eli Lilly (LLY) to Buy Following Strong First-Half Results",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical company. The stock has surged by over 4% since the start of 2025. E​rste Group raised its ratin‍g on Eli Lilly and Company (NYSE:LLY) from Ho⁠ld‍ to Buy […]",
    "url": "https://finnhub.io/api/news?id=4cd6ce88d2c2c1715c200f5f5be616b7de37b44cc2df714330b90eae39bdf55b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760592874,
      "headline": "Erste Group Upgrades Eli Lilly (LLY) to Buy Following Strong First-Half Results",
      "id": 137101903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical company. The stock has surged by over 4% since the start of 2025. E​rste Group raised its ratin‍g on Eli Lilly and Company (NYSE:LLY) from Ho⁠ld‍ to Buy […]",
      "url": "https://finnhub.io/api/news?id=4cd6ce88d2c2c1715c200f5f5be616b7de37b44cc2df714330b90eae39bdf55b"
    }
  }
]